ASCO GU 2023: Outcomes of patients with kidney cancer brain metastases treated with first-line therapies
At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
Genetic biomarkers for the survival of kidney cancer patients
Previously, researchers found some genes that helped identify which patients [...]
International Kidney Cancer Symposium (IKCS) 2021
The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
Pegilodecakin for metastatic kidney cancer
Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors [...]
ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
EIKCS 2021: Future treatments for metastatic kidney cancer
Despite the advances in first-line treatments for metastatic renal cell [...]
EIKCS 2021: Second-line and later treatments for metastatic kidney cancer
The increase in the number of first-line treatments for metastatic [...]
EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?
The use of combination therapies for the first-line treatment of [...]
